Ocular Therapeutix's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.46.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.94.
During the past 3 years, the average EBIT per Share Growth Rate was 2.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ocular Therapeutix's EBIT per Share or its related term are showing as below:
OCUL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -2.8 Med: 15.1 Max: 29.2
Current: 2.4
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Ocular Therapeutix was 29.20% per year. The lowest was -2.80% per year. And the median was 15.10% per year.
OCUL's 3-Year EBIT Growth Rate is ranked worse than 51.41% of 1313
companies
in the Biotechnology industry
Industry Median: 3.5
vs OCUL: 2.40
The historical data trend for Ocular Therapeutix's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (NAS:OCUL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ocular Therapeutix EBIT per Share Related Terms
Thank you for viewing the detailed overview of Ocular Therapeutix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocular Therapeutix (Ocular Therapeutix) Business Description
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCUL has been successfully added to your 